Jenburkt Pharma Financial Statements

Jenburkt Pharma (JENBURKT) reported revenue of ₹1.52B in FY2025 with net income of ₹320.61M. Total assets stood at ₹1.96B and free cash flow was ₹81.92M.

Jenburkt Pharma Income Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Revenue		1.14B	1.24B	1.37B	1.42B	1.52B
Cost of Rev. Cost of Revenue		-300.98M	-314.35M	-330.04M	-304.11M	-296.57M
Gross Profit		835.04M	925.46M	1.04B	1.12B	1.22B
SGA Sales, General & Admin		-593.54M	-364.91M	-388.07M	-424.89M	-455.36M
Op. Income Operating Income		221.15M	253.57M	281.09M	307.80M	376.65M
PBT Profit Before Tax		216.42M	298.71M	328.65M	351.76M	439.33M
Net Income		165.02M	222.97M	246.07M	259.77M	320.61M
Dil. Shares Diluted Shares		4.59M	4.59M	4.41M	4.41M	4.41M
Diluted EPS		35.96	48.58	53.90	58.86	72.65

Figures in ₹ — millions (M), billions (B), trillions (T). EPS is earnings per share.

Understanding the Income Statement

The income statement shows Jenburkt Pharma's revenue and expenses over a period. Revenue minus costs gives gross profit; after operating expenses, interest, and taxes, the remainder is net income. Diluted EPS divides net income by all shares that could exist if options and convertibles were exercised.

Jenburkt Pharma Balance Sheet

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Curr. assets Total current assets		799.21M	759.04M	810.91M	1.10B	565.32M
Non-curr. assets Total non-current assets		404.59M	670.45M	607.21M	553.72M	1.40B
Total assets		1.20B	1.43B	1.42B	1.65B	1.96B
Curr. liabilities Total current liabilities		179.26M	212.80M	157.62M	163.79M	188.19M
Non-curr. liab. Total non-current liabilities		39.88M	42.87M	36.61M	37.80M	55.90M
Total liabilities		219.14M	255.67M	194.23M	201.59M	244.09M
Total equity		984.66M	1.17B	1.22B	1.45B	1.72B
Total liab. & eq. Total liabilities & equity		1.20B	1.43B	1.42B	1.65B	1.96B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding the Balance Sheet

The balance sheet captures Jenburkt Pharma's financial position at a point in time — what it owns (assets), what it owes (liabilities), and the residual value to shareholders (equity). Total assets always equals total liabilities plus equity.

Jenburkt Pharma Cash Flow Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Net Income		165.02M	222.97M	246.07M	259.77M	320.61M
Operating CF Cash flow Operating Activities		194.55M	92.71M	170.52M	81.24M	279.06M
Capex Investments in PPE		-11.45M	-30.54M	-21.05M	-25.54M	-197.14M
Investing CF Cash flow Investing Activities		-187.81M	-12.02M	26.18M	-5.80M	-170.45M
Dividend Paid		-1.44M	-46.80M	-55.00M	-63.18M	-67.81M
Financing CF Cash flow Financing Activities		-7.14M	-55.31M	-210.41M	-70.78M	-76.22M
Cash (start) Cash at beginning of period		25.34M	24.94M	50.31M	36.60M	41.25M
Cash (end) Cash at end of period		24.94M	50.31M	36.60M	41.25M	73.65M
FCF Free Cash Flow		183.10M	62.17M	149.48M	55.70M	81.92M

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding Cash Flow

The cash flow statement tracks how Jenburkt Pharma's cash moves through operations, investing, and financing activities. Free cash flow — operating cash minus capital expenditure — shows what is available to return to shareholders.

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025